FY2025 Earnings Forecast for Cresco Labs Issued By Cormark

Key Points

• Cormark has revised its FY2025 earnings estimate for Cresco Labs, lowering the expected earnings per share from ($0.07) to ($0.14), while the consensus estimate stands at ($0.20).
• Shares of Cresco Labs have been downgraded by Canaccord Genuity Group from a "strong-buy" to a "moderate buy" rating.
• Cresco Labs reported a quarterly earnings loss of ($0.05) EPS, missing the consensus estimate by one cent, while revenue for the quarter was $163.62 million.

Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Cormark lowered their FY2025 earnings estimates for shares of Cresco Labs in a note issued to investors on Monday, August 11th. Cormark analyst J. Pytlak now anticipates that the company will post earnings per share of ($0.14) for the year, down from their previous estimate of ($0.07). The consensus estimate for Cresco Labs' current full-year earnings is ($0.20) per share. Cormark also issued estimates for Cresco Labs' FY2026 earnings at ($0.06) EPS.

Separately, Canaccord Genuity Group cut shares of Cresco Labs from a "strong-buy" rating to a "moderate buy" rating in a research report on Tuesday, June 3rd.

Cresco Labs Trading Up 5.1%

CRLBF stock opened at $1.04 on Wednesday. The company has a fifty day moving average price of $0.58 and a two-hundred day moving average price of $0.70. The stock has a market cap of $510.66 million, a price-to-earnings ratio of -8.00 and a beta of 1.42. Cresco Labs has a one year low of $0.43 and a one year high of $2.05. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.10 and a quick ratio of 1.98.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.01). Cresco Labs had a negative return on equity of 11.77% and a negative net margin of 6.67%. The company had revenue of $163.62 million for the quarter, compared to the consensus estimate of $162.00 million.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.